|
Synonyms: Anthim® | ETI-204 | Nyxthracis®
obiltoxaximab is an approved drug (FDA (2016), EMA (2020))
Compound class:
Antibody
Comment: Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody that binds the protective antigen (PA) component of Bacillus anthracis toxin.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| References |
|
1. Greig SL. (2016)
Obiltoxaximab: First Global Approval. Drugs, 76 (7): 823-30. [PMID:27085536] |
